Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.

Literature DB >> 23637382

Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.

Philip J Kahn, Randy Q Cron.

Abstract

Mesh：

Substances：

Year: 2013 PMID： 23637382 DOI： 10.3899/jrheum.121098

Source DB: PubMed Journal: J Rheumatol ISSN： 0315-162X Impact factor: 4.666

Keyword Cloud
Cited

× No keyword cloud information.

19 in total

Review 1. Environmental immune disruptors, inflammation and cancer risk.

Authors: Patricia A Thompson; Mahin Khatami; Carolyn J Baglole; Jun Sun; Shelley A Harris; Eun-Yi Moon; Fahd Al-Mulla; Rabeah Al-Temaimi; Dustin G Brown; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Leroy Lowe; Tiziana Guarnieri; William H Bisson
Journal: Carcinogenesis Date: 2015-06 Impact factor: 4.944

Review 2. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.

Authors: Hafize Emine Sönmez; Selcan Demir; Yelda Bilginer; Seza Özen
Journal: Clin Rheumatol Date: 2018-04-16 Impact factor: 2.980

Review 3. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors: Lauren A Henderson; Randy Q Cron
Journal: Paediatr Drugs Date: 2020-02 Impact factor: 3.022

Review 4. An expanding role for interleukin-1 blockade from gout to cancer.

Authors: Charles Anthony Dinarello
Journal: Mol Med Date: 2014-12-16 Impact factor: 6.354

5. A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.

Authors: Mingce Zhang; Claudia Bracaglia; Giusi Prencipe; Christina J Bemrich-Stolz; Timothy Beukelman; Reed A Dimmitt; W Winn Chatham; Kejian Zhang; Hao Li; Mark R Walter; Fabrizio De Benedetti; Alexei A Grom; Randy Q Cron
Journal: J Immunol Date: 2016-02-15 Impact factor: 5.422

6. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Authors: Bita Shakoory; Joseph A Carcillo; W Winn Chatham; Richard L Amdur; Huaqing Zhao; Charles A Dinarello; Randall Q Cron; Steven M Opal
Journal: Crit Care Med Date: 2016-02 Impact factor: 7.598

Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.

Review 1. Environmental immune disruptors, inflammation and cancer risk.

Review 2. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.

Review 3. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Review 4. An expanding role for interleukin-1 blockade from gout to cancer.

5. A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.

6. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Review 7. Treating inflammation by blocking interleukin-1 in humans.

8. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.

Review 9. Ebola Virus Disease has Features of Hemophagocytic Lymphohistiocytosis Syndrome.

Review 10. Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis.